OCREVUS (also known as Ocrelizumab)
Ocrevus is an antibody that targets CD20 on B lymphocytes which lead to destruction of those problematic cells. Ocrevus was approved in March 2017 by the FDA and is a new tool for a disease like multiple sclerosis (MS), which is thought to be caused by white blood cells attacking the central nervous system.
Patients with relapsing or primary progressive forms of multiple sclerosis.
Patients with active hepatitis B virus infection should not be started on Ocrevus.
Ocrevus is typically administered as an infusion. The starting dose is divided into two infusions spread two weeks apart; the initial infusions are administered over 2.5 hours. Subsequent doses are repeated every 6 months; the maintenance infusions are administered over 3.5 hours.